Zhijian Xu, Song Yang, Lina Zhu, Xing Wan, Hu Xu, Huahui Chen, Lude Wang, Minfeng Tong, Qi Tu
{"title":"Visual impairment as the initial presentation in multiple myeloma: a case report and literature review.","authors":"Zhijian Xu, Song Yang, Lina Zhu, Xing Wan, Hu Xu, Huahui Chen, Lude Wang, Minfeng Tong, Qi Tu","doi":"10.21037/tcr-24-511","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Multiple myeloma (MM) is a type of blood cancer, which rarely infiltrates the central nervous system (CNS) and lacks specific neurological symptoms. The prognosis is often poor, as the disease progresses rapidly. Herein, we present a rare case of MM with CNS involvement.</p><p><strong>Case description: </strong>A 53-year-old man was admitted to the Neurosurgery Department, Jinhua Hospital Affiliated to Zhejiang University with initial symptoms of \"blurred vision for 3 months accompanied by numbness on the right side of the face for 7 days\". Enhanced cranial magnetic resonance imaging revealed a tumor deep in the right temporal bone. During exploratory surgery, the \"fleshy\" mass was completely removed. Postoperative pathology confirmed a diagnosis of \"plasmacytoma with intermediate features\". The patient received multiple systematic chemotherapy treatments after surgery in the department of hematology of Jinhua Hospital Affiliated to Zhejiang University. During a 10-month follow-up period, the patient's neurological symptoms improved, and his general condition was considered good.</p><p><strong>Conclusions: </strong>This report summarizes the clinical features, diagnosis, treatment, and prognosis of a patient with MM involving the CNS and examines the relevant literature. This case may serve as a reference for future clinical treatment and diagnosis. Further research on the pathophysiology of such cases is warranted.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"13 9","pages":"5149-5156"},"PeriodicalIF":1.5000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11483438/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-511","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/18 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Multiple myeloma (MM) is a type of blood cancer, which rarely infiltrates the central nervous system (CNS) and lacks specific neurological symptoms. The prognosis is often poor, as the disease progresses rapidly. Herein, we present a rare case of MM with CNS involvement.
Case description: A 53-year-old man was admitted to the Neurosurgery Department, Jinhua Hospital Affiliated to Zhejiang University with initial symptoms of "blurred vision for 3 months accompanied by numbness on the right side of the face for 7 days". Enhanced cranial magnetic resonance imaging revealed a tumor deep in the right temporal bone. During exploratory surgery, the "fleshy" mass was completely removed. Postoperative pathology confirmed a diagnosis of "plasmacytoma with intermediate features". The patient received multiple systematic chemotherapy treatments after surgery in the department of hematology of Jinhua Hospital Affiliated to Zhejiang University. During a 10-month follow-up period, the patient's neurological symptoms improved, and his general condition was considered good.
Conclusions: This report summarizes the clinical features, diagnosis, treatment, and prognosis of a patient with MM involving the CNS and examines the relevant literature. This case may serve as a reference for future clinical treatment and diagnosis. Further research on the pathophysiology of such cases is warranted.
期刊介绍:
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.